Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
Date: February 25, 2011
Receipt Date: May 13, 2011
Earliest Anticipated Start Date: July 1, 2011
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse announces an
administrative supplement program to provide funds to supported research
projects for research for the Study of Remote Physiological Monitoring of
Cocaine use can be clinically manifested with signs and symptoms that vary depending on the purity of the used drug, route of administration, amount and frequency of use as well as individual differences such as plasma cholinesterase levels and tolerance level, and the concomitant use of other drugs. The signs and symptoms of cocaine use develop soon after its ingestion and are characterized by intense cardiovascular excitation (e.g, tachycardia, hypertension, and arrhythmias), vasoconstriction, increased psychomotor activity, hyperreflexia, fasciculations (particularly in the face and extremities), mydriasis, diaphoresis, hyperthermia, and tachypnea.
A critical limitation in the development of treatments for cocaine use disorders is the lack of real-time and objective measures of cocaine use. Technological advances are allowing the real-time evaluation of physiological changes, often sparing the patient from visiting a doctor’s office or a clinical laboratory to perform a test and obtain the result. Remote physiological monitoring (RPM) is a form of telemedicine that is rapidly developing. It uses technology to track patients’ health status without face-to-face contact. Health parameters, such as heart rate, heart rhythm, blood pressure, oxygen saturation, skin temperature, and glucose levels, among others, can be measured using devices that can store and or transmit the results in real-time. Given the multiple and measurable clinical manifestations of cocaine use, an RPM device to evaluate the clinical manifestations of cocaine use is not only feasible but also can offer multiple clinical and research applications.
The purpose of this supplement is to provide funds to
qualified investigators to evaluate existing remote monitoring tools to measure
in real-time the physiological and clinical manifestations of cocaine use. The
goal of this supplement request is to identify and test RPM tool(s) that can
potentially provide valid and reliable data about the amount and frequency of
cocaine use among cocaine users in their natural settings. It is expected that
such device could be used to monitor cocaine use in clinical trials of
therapeutic interventions for cocaine dependence and eventually be used by
clinicians to monitor cocaine use in patients receiving treatment.
Supplement requests may not exceed $95,000 (direct costs).
The supplement request is for one year of funding. Applicants must hold an active grant funded by NIDA, under the following mechanisms: R01, U01, U10, U19, P01, P20, P50 and P60; with a current project period end date of October 1st, 2012 or later. The duration of the award may not exceed the end date of the active parent grant and the proposed research must be within the scope of the parent grant. Any no cost extension should be in place before submission. Before submitting a supplement application, potential applicants are highly encouraged to contact the program official of the parent grant to discuss the supplement plan and determine the responsiveness and pertinence of the potential application.
eligible, the parent grant must be active, and the research proposed in the
supplement must be accomplished within the competitive segment. The proposed
supplement must be within the general scope of the peer-reviewed activities and
aims approved within the parent grant.
IMPORTANT: The research proposed by the NIH grantee in the supplement application must be within the original scope of the NIH-supported grant project. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives as long as they are within the original scope of the project. Any cost increases need to result from making modifications to the project in order to take advantage of opportunities that would increase the value of the project consistent with its originally approved objectives and purposes.
To be considered for an administrative supplement, the request must be signed by the Authorized Organizational Representative/Signing Official (AOR/SO), and must describe the need for additional funding and the categorical costs.
Administrative supplement requests should be sent as attachments in an email to: NIDAGMBemail@mail.nih.gov.
Applicants who prefer to submit hard copy (paper) requests should send them to:
6001 Executive Boulevard
Room 4218, MSC 9560
Bethesda, MD 20892-9560, or for express delivery please use
Rockville, MD 20852
Requests should be submitted on the PHS398
Application Guide forms (font size and other formatting rules apply as
designated in the instructions), as indicated below. Include only the following
Cover Letter which cites this Notice, and the following information:
PHS 398 Form Page 1 (Face page)
PHS 398 Form Page 2
A brief proposal describing the project, including:
Budget for the supplement with a justification that details the items requested, including Facilities and Administrative costs. Should be in the same budget format as the Parent Grant.
Supplement applications can be submitted at any time, but not later than 5 PM EST of May 13, 2011.
Administrative supplement requests will be reviewed administratively by NIH Staff. Selection factors will include the following:
Applications will be reviewed administratively. The review criteria include the feasibility of using the RPM tool, its clinical pertinence, expertise of the key personnel involved, availability of resources to conduct the study, quality of the research methods, the relevance of the supplement to the aims of the parent grant, and the quality of the progress of the parent grant.
Inquiries and discussion of plans for responding to this
Notice are strongly encouraged.
Ivan D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse
6001 Executive Blvd. Room 4131
Bethesda, MD 20892
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.